NCT06717022

A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors

A Clinical Study of CHT102, a Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T) for Mesothelin(MSLN) Positive Advanced Solid Tumors: a Single-arm, Open-label, Dose Escalation and Expansion Clinical Study

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Objectives of Study：In this study investigators plan to evaluate the safety and efficacy of MSLN-targeting Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T) in the treatment of MSLN-positive advanced solid tumors.

Conditions

• Mesothelin Positive Tumors

Interventions

Type	Name	Description
BIOLOGICAL	CHT102 allogeneic CAR T cells	CHT102 allogeneic CAR T cells

Timeline

• Start date: 2024-05-06
• Primary completion: 2026-06-01
• Completion: 2039-05-01
• First posted: 2024-12-04
• Last updated: 2024-12-04

Locations

1 site across 1 country: China